Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination between Social Capital Suvretta Holdings Corp. III ("SCS") and ProKidney LP on July 11, 2022. Following the closing, the registrant changed its name to ProKidney Corp. ("New ProKidney") and began trading on the Nasdaq Capital Market under the symbol "PROK" on July 12, 2022. The transaction fulfilled the requirement for SCS to cease being a shell company.
Key Financial Metrics and Capital Structure
Capital Raised and Liquidity:
- PIPE Investment: New ProKidney issued 52,480,000 Class A ordinary shares and 5,000,000 Post-Combination ProKidney Common Units to PIPE investors at $10.00 per share/unit, raising an aggregate of $574.8 million.
- Redemptions: Approximately 22,829,769 public shares were redeemed for approximately $10.00 per share, totaling approximately $228.3 million.
- Trust Account Balance: Approximately $21.7 million remained in the Trust Account after redemptions and transaction expenses, to be used for general corporate purposes.
- Transaction Costs: Placement agent fees totaled approximately $34.8 million (including deferred underwriting fees), with additional finder's fees of $1.0 million and financial advisor fees of $0.5 million.
Equity Outstanding:
- Immediately following the closing, 232,264,192 ordinary shares were outstanding.
- Executive officers and directors and their affiliated entities held 44.6% of the outstanding ordinary shares.
Revenue and Profit: The filing text does not provide specific revenue, profit, or cash flow figures for the reporting period; it refers readers to the Proxy Statement for unaudited pro forma condensed combined financial information.
Material Changes and Corporate Actions
- Name Change: The company changed its name from Social Capital Suvretta Holdings Corp. III to ProKidney Corp.
- Accountant Change: The audit committee dismissed Marcum LLP and appointed Ernst & Young LLP ("EY") as the independent registered public accounting firm. This change followed a determination that SCS had a material weakness in internal controls over financial reporting as of March 31, 2022, related to the accounting for complex financial instruments.
- Management Changes: All incumbent SCS directors and officers resigned, except Uma Sinha, Ph.D. Jennifer Fox was appointed to the Board of Directors and the Audit Committee.
- Shareholder Rights: The company adopted a Second Amended and Restated Memorandum and Articles of Association, establishing a staggered board of directors and eliminating cumulative voting.
Guidance, Risks, and Contingencies
Forward-Looking Statements: The filing contains forward-looking statements regarding the anticipated benefits of the business combination, product development, and financial condition. These are subject to significant risks and uncertainties.
Key Risks Identified:
- Success, cost, and timing of product development activities, specifically for the lead product candidate, Renal Autologous Cell Therapy (REACT).
- Complexity and potential delays in manufacturing cell therapies.
- Ability to obtain and maintain regulatory approval.
- Reliance on third parties for research, nonclinical testing, and clinical trials.
- Competition from companies with greater financial and marketing resources.
- Need for additional financing to fund operations and development.
Lock-Up Agreements: Significant restrictions on transfer apply to SCS Sponsor III LLC and certain ProKidney Unitholders. Restrictions generally expire 180 days after closing, with certain shares subject to price-based triggers ($12.50 and $15.00 per share) or regulatory authorization milestones.
Investor Verification Checklist
- Verify the pro forma financial condition and cash runway by reviewing the "Unaudited Pro Forma Condensed Combined Financial Information" in the Proxy Statement (pages 82 and 181).
- Confirm the status of the material weakness in internal controls identified by Marcum LLP and the remediation plan implemented by EY.
- Review the specific terms of the Tax Receivable Agreement, under which the company must pay 85% of certain tax savings to former unitholders.
- Monitor the lock-up expiration dates and price triggers for significant shareholders, particularly Tolerantia, LLC and Control Empresarial de Capitales, S.A. de C.V.
- Assess the progress and regulatory timeline for the lead product candidate, REACT, as commercialization is not yet achieved.